Fusion Antibodies (LON:FAB) Trading Up 2% – Still a Buy?

Fusion Antibodies plc (LON:FAB) shares traded up 2% on Tuesday . The stock traded as high as GBX 11.40 and last traded at GBX 10.71. Approximately 159,643 shares traded hands during trading, a decline of 60% from the average session volume of 402,811 shares. The stock had previously closed at GBX 10.50.

Fusion Antibodies Stock Performance

The company has a market capitalization of £14.14 million, a price-to-earnings ratio of -7.53 and a beta of 1.22. The company has a current ratio of 1.80, a quick ratio of 2.36 and a debt-to-equity ratio of 92.42. The stock’s fifty day simple moving average is GBX 10.88 and its 200-day simple moving average is GBX 12.46.

Fusion Antibodies Company Profile

Fusion is a Belfast based contract research organisation (“CRO”) providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.

The Company’s ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion’s proprietary CDRx TM platform and the production of antibody generating stable cell lines to provide material for use in clinical trials.